Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients

Nicole L. Lanza, Allison L. McClellan, Hatim Batawi, Elizabeth R. Felix, Konstantinos D. Sarantopoulos, Roy C. Levitt, Anat Galor

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Purpose To compare dry eye (DE) symptoms and signs in subjects who tested positive versus those who tested negative for ocular surface matrix metalloproteinase 9 (MMP-9) using the InflammaDry point-of-care test (RPS, Sarasota, FL). Methods In this cross-sectional study, individuals seen in the Miami Veterans Affairs eye clinic with DE symptoms, as evidenced by DE questionnaire 5 (DEQ5) ≥6, were given standardized questionnaires to assess DE symptoms and ocular and non-ocular pain complaints. Also, a complete evaluation was conducted to measure ocular surface signs of DE. MMP-9 testing was performed using the InflammaDry once in each eye, per the manufacturer's instructions. The main outcome measure was a comparison of DE symptoms and signs in MMP-9 positive versus negative subjects. Results Of 128 subjects, 50 (39%) were positive for MMP-9 for InflammaDry testing in either eye. No statistically significant differences in mental health indices, DE symptoms, or ocular surface signs were seen in subjects based on MMP-9 status. Conclusion In our population, there was no difference in the DE profile by both symptoms and signs between those testing positive versus negative for MMP-9 on the ocular surface. This suggests that clinical exam alone cannot predict patients with clinically significant inflammation.

Original languageEnglish (US)
Pages (from-to)216-223
Number of pages8
JournalOcular Surface
Volume14
Issue number2
DOIs
StatePublished - Apr 1 2016

Keywords

  • InflammaDry
  • dry eye
  • matrix metalloproteinase-9

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients'. Together they form a unique fingerprint.

Cite this